Navigation Links
Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
Date:4/17/2008

JENA, Germany, April 17 /PRNewswire/ -- Occlutech GmbH, the leading European manufacturer of cardiac occlusion devices today announced a clarification of a recent news release.

In a news release dated February 8th, 2008, Occlutech stated that it received an opinion from AIPPI the European "Association for the Protection of Intellectual Property" with regard to non infringement by Occlutech of certain European IP held by AGA Medical.

AIPPI has requested a clarification of this statement:

1) The name European International Association for the Protection of Intellectual Property was not stated correctly. The correct name is the "International Association for the Protection of Intellectual Property".

2) The opinion received by Occlutech which states that Occlutech is not infringing EP 0808138B1 and its Italian part 019020BE/2006 held by AGA Medical Corp was commissioned through the Italian National Group of AIPPI but not issued by AIPPI International itself. The opinion was issued by and in the name of three independent experts nominated by the Italian Group of AIPPI. The opinion was issued by the experts nominated by the Italian Branch of AIPPI and not by, in the name of or on behalf of AIPPI International or the Italian National Group of AIPPI.

The opinion was given without influence of Occlutech GmbH and the impartiality of the experts has subsequently been confirmed by the Italian Branch of AIPPI.

3) Such an independent opinion commissioned through AIPPI is an instrument aiming at giving the requiring party a qualified and impartial opinion. It does not represent an official opinion by AIPPI since AIPPI does not get involved in intellectual property disputes between parties on behalf or in favour of one of the parties.

Occlutech GmbH regrets that its communication was not clear with regard to the role of AIPPI in commissioning and receiving the opinion.

Occlutech GmbH develops and manufactures a wide range of occluders that are sold under the Occlutech Figulla N brand in over 40 countries in European and international markets. Clinical programs leading to regulatory approval in the US and Japan are underway.

Contact:

Robert Moszner

e-mail: robert.moszner@occlutech.com

Phone: +49-3641-67-51-20

Susanne Goransson

e-mail: info@occlutech.info

Phone: +46-704336521


'/>"/>
SOURCE Occlutech GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
2. Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions
3. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
4. Oncothyreon announces effectiveness of shelf registration statement
5. WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering
6. Evotecs Registration Statement in Connection With its Proposed Acquisition of Renovis Declared Effective
7. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
8. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
9. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
10. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
11. APIC Statement on Need for Increased Prevention Measures for Healthcare-Associated Infections (HAIs)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... ... 2016 , ... In a new case report published today in STEM CELLS ... developed lymphedema after being treated for breast cancer benefitted from an injection of stem ... with this debilitating, frequent side effect of cancer treatment. , Lymphedema refers ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... of the QB3@953 life sciences incubator to ... health. The shared laboratory space at QB3@953 was created ... a key obstacle for many early stage organizations - ... of the sponsorship, Amgen launched two "Amgen Golden Ticket" ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
Breaking Biology News(10 mins):